Combination therapy of anti-HER3 antibodies
The present invention relates to the combination therapy of anti-HER3 antibodies with certain anti-HER antibodies.
1. A method of treating a patient suffering from a HER2-normal cancer wherein the method comprises the co-administration of an antibody which binds to human HER3 in combination with an antibody which binds to human HER2 and which inhibits dimerization of HER2, wherein the antibody which binds to human HER3 comprises a heavy chain variable domain comprising a CDR3H region of SEQ ID NO: 1, a CDR2H region of SEQ ID NO: 2, and a CDR1H region of SEQ ID NO:3, and a light chain variable domain comprising a CDR3L region of SEQ ID NO: 4 a CDR2L region of SEQ ID NO:5, and a CDR1L region of SEQ ID NO:6 or a CDR1L region of SEQ ID NO:7.
2. The method of claim 1 , wherein the antibody which binds to human HER3 is characterized in that the heavy chain variable domain comprises a CDR3H region of SEQ ID NO: 1, a CDR2H region of SEQ ID NO: 2, and a CDR1H region of SEQ ID NO:3, and the light chain variable domain comprises a CDR3L region of SEQ ID NO: 4, a CDR2L region of SEQ ID NO:5, and a CDR1L region of SEQ ID NO:7.
3. The method of claim 1 , wherein the antibody which binds to human HER3 is characterized in that
the heavy chain variable domain VH is SEQ ID NO:8; and the light chain variable domain VL is SEQ ID NO:10.
4. The method of claim 1 , wherein the antibody which binds to human HER3 is characterized in that it is glycosylated with a sugar chain at Asn297 whereby the amount of fucose within said sugar chain is 65% or lower.
5. The method of claim 1 , wherein the antibody which binds to human HER2 and which inhibits dimerization of HER2 is pertuzumab.
6. The method of claim 1 , wherein the cancer is characterized by a HER3 expression.
7. The method of claim 1 , wherein the cancer is breast cancer, ovarian cancer, gastric cancer, prostate cancer, pancreatic cancer or cancer of the head or neck breast cancer.
8. A method of treating a patient suffering from a cancer which expresses HER3 or HER1 or both HER3 and HER1 wherein the method comprises the co-administration of an antibody which binds to human HER3 in combination with an antibody which binds to human HER1, wherein at least one of the antibody which binds to human HER3 and the antibody which binds to human HER1 is characterized in that the antibody is glycosylated with a sugar chain at Asn297 whereby the amount of fucose within said sugar chain is 65% or lower, and wherein the antibody which binds to human HER3 comprises a heavy chain variable domain comprising a CDR3H region of SEQ ID NO: 1, a CDR2H region of SEQ ID NO: 2, and a CDR1H region of SEQ ID NO:3, and a light chain variable domain comprising a CDR3L region of SEQ ID NO: 4, a CDR2L region of SEQ ID NO:5, and a CDR1L region of SEQ ID NO:7.
9. The method of claim 8 , wherein both the antibody which binds to human HER3 and the antibody which binds to human HER1, are characterized in being glycosylated with a sugar chain at Asn297 whereby the amount of fucose within said sugar chain is 65% or lower.
10. The method of claim 8 , wherein the antibody which binds to human HER3 is characterized in that
the heavy chain variable domain VH is SEQ ID NO:8; and the light chain variable domain VL is SEQ ID NO:10.
11. The method of claim 8 , wherein the antibody which binds to human HER1 is characterized in that
the heavy chain variable domain VH is SEQ ID NO:20; and the light chain variable domain VL is SEQ ID NO:21.
12. The method of claim 10 , wherein the antibody which binds to human HER1 is characterized in that
the heavy chain variable domain VH is SEQ ID NO:20; and the light chain variable domain VL is SEQ ID NO:21.
13. The method of claim 8 , wherein the cancer is lung cancer or breast cancer, colorectal cancer, or head and neck cancer.
14. The method of claim 8 , wherein the cancer expresses HER3 and HER1.
15. The method of claim 12 , wherein the cancer expresses HER3 and HER1.